BOSTON, MA, Superluminal Medicines, a generative biology and chemistry company, announced the closing of a $33 million funding round.
Superluminal Medicines Inc., a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created, announced the closing of a $33 million funding round. The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA. Gaingels also joined in the financing.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
